Investigating Novel Immunotherapy Combinations for Advanced Gastric and Esophageal Cancers
By Samuel Cytryn, MD - Last Updated: March 19, 2025Samuel Cytryn, MD, of Memorial Sloan Kettering Cancer Center, highlights his phase II trial in progress, presented at the 2025 ASCO Gastrointestinal Cancers Symposium, investigating a novel immunotherapy combination for advanced, refractory gastroesophageal adenocarcinoma. The study evaluates the use of agenT-797 (allogeneic invariant natural killer T-cells), botensilimab (a CTLA-4 inhibitor), and balstilimab (a PD-1 inhibitor), in combination with standard treatments ramucirumab and paclitaxel.
Advertisement
Advertisement
Related Posts
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Of subtypes in KEYNOTE-059 and -061, HRD scores and TMB were highest in CIN and MSI-H subtypes, respectively.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.